Previous close | 3.8300 |
Open | 3.8900 |
Bid | 3.9400 x 100 |
Ask | 3.9900 x 100 |
Day's range | 3.7950 - 3.9600 |
52-week range | 2.7650 - 5.1900 |
Volume | |
Avg. volume | 354,688 |
Market cap | 333.523M |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript February 28, 2024 Atea Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update […]
Highlights Clinical Progress and Financial Position
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.